Disease-associated functions of IL-33: The new kid in the IL-1 family

Nature Reviews Immunology

Volumn 10, Issue 2, 2010, Pages 103-110

  Liew, Foo Y ^a   Pitman, Nick I ^a   McInnes, Iain B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 33;

ANAPHYLAXIS; ARTHRITIS; ASTHMA; ATHEROSCLEROSIS; ATOPIC DERMATITIS; ATOPY; CARDIOVASCULAR DISEASE; DRUG TARGETING; HELMINTHIASIS; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION; INFLAMMATORY DISEASE; MAST CELL; NONHUMAN; PAIN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL;

ANAPHYLAXIS; ANIMALS; ASTHMA; ATHEROSCLEROSIS; DERMATITIS, ATOPIC; HELMINTHIASIS; HUMANS; INTERLEUKIN-1; INTERLEUKINS; MAST CELLS; TH2 CELLS;

EID: 75549087056     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2692     Document Type: Review

References (69)

1. Schmitz, J. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490 (2005).
2. Tominaga, S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 258, 301-304 (1989).
3. Xu, D. et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J. Exp. Med. 187, 787-794 (1998). (Pubitemid 28115194)
4. Lohning, M. et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc. Natl Acad. Sci. USA 95, 6930-6935 (1998).
5. Coyle, A. J. et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J. Exp. Med. 190, 895-902 (1999).
6. Sanada, S. et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 11 7, 1538-1549 (2007)
7. Moussion, C., Ortega, N. & Girard, J. P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One. 3, e3331 (2008).
8. Miller, A. M. et al. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205, 339-346 (2008).
9. Carriere, V. et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl Acad. Sci. USA 104, 282-287 (2007).
10. Baekkevold, E. S. et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am. J. Pathol. 163, 69-79 (2003).
11. Roussel, L., Erard, M., Cayrol, C. & Girard, J. P. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. 9, 1006-1012 (2008).
12. Cayrol, C. & Girard, J. P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc. Natl Acad. Sci. USA 106, 9021-9026 (2009).
13. Luthi, A. U. et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31, 84-98 (2009).
14. Talabot-Ayer, D., Lamacchia, C., Gabay, C. & Palmer, G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J. Biol. Chem. 284, 19420-19426 (2009).
15. Lamkanfi, M. et al. Targeted peptidecentric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. Mol. Cell. Proteomics 7, 2350-2363 (2008).
16. Hayakawa, M. et al. Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem. Biophys. Res. Commun. 387, 218-222 (2009).
17. Wessendorf, J. H., Garfinkel, S., Zhan, X., Brown, S. & Maciag, T. Identification of a nuclear localization sequence within the structure of the human interleukin-1 a precursor. J. Biol. Chem. 268, 22100-22104 (1993).
18. Eigenbrod, T., Park, J. H., Harder, J., Iwakura, Y. & Nunez, G. Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1a released from dying cells. J. Immunol. 181, 8194-8198 (2008).
19. Sakurai, T. et al. Hepatocyte necrosis induced by oxidative stress and IL-1 a release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14, 156-165 (2008).
20. Klune, J. R., Dhupar, R., Cardinal, J., Billiar, T. R. & Tsung, A. HMGB1: endogenous danger signaling. Mol. Med. 14, 476-484 (2008).
21. Kazama, H. et al. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29, 21-32 (2008).
22. Scaffidi, P., Misteli, T. & Bianchi, M. E. Release of chromatin protein HMGB 1 by necrotic cells triggers inflammation. Nature 418, 191-195 (2002).
23. Oppenheim, J. J. & Yang, D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 17, 359-365 (2005).
24. Bianchi, M. E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81, 1-5 (2007).
25. Pushparaj, P. N. et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc. Natl Acad. Sci. USA 106, 9773-9778 (2009).
26. Chackerian, A. A. et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 179, 2551-2555 (2007).
27. Ali, S. et al. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc. Natl Acad. Sci. USA 104, 18660-18665 (2007).
28. Funakoshi-Tago, M. et al. TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell. Signal. 20, 1679-1686 (2008).
29. Allakhverdi, Z., Smith, D. E., Comeau, M. R. & Delespesse, G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J. Immunol. 179, 2051-2054 (2007).
30. Moulin, D. et al. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40, 216-225 (2007).
31. + T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol. 181, 4780-4790 (2008).
32. Arend, W. P., Palmer, G. & Gabay, C. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 223, 20-38 (2008).
33. Iikura, M. et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab. Invest. 87, 971-978 (2007).
34. Ho, L. H. et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcsRI signals. J. Leukoc. Biol. 82, 1481-1490 (2007).
35. Hayakawa, H., Hayakawa, M., Kume, A. & Tominaga, S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J. Biol. Chem. 282, 26369-26380 (2007).
36. Komai-Koma, M. et al. IL-33 is a chemoattractant for human Th2 cells. Eur. J. Immunol. 37, 2779-2786 (2007).
37. Smithgall, M. D. et al. IL-33 amplifies both Th1-and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int. Immunol. 20, 1019-1030 (2008).
38. Bourgeois, E. et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-γ production. Eur. J. Immunol. 39, 1046-1055 (2009).
39. Suzukawa, M. et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J. Immunol. 181, 5981-5989 (2008).
40. Kurowska-Stolarska, M. et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 183, 6469-6477 (2009).
41. Cherry, W. B., Yoon, J., Bartemes, K. R., Iijima, K. & Kita, H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J. Allergy Clin. Immunol. 121, 1484-1490 (2008).
42. Suzukawa, M. et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab. Invest. 88, 1245-1253 (2008).
43. Espinassous, Q. et al. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J. Immunol. 183, 1446-1455 (2009).
44. H2-type response. J. Allergy Clin. Immunol. 123, 1047-1054 (2009).
45. Humphreys, N. E., Xu, D., Hepworth, M. R., Liew, F. Y. & Grencis, R. K. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J. Immunol. 180, 2443-2449 (2008).
46. Walzl, G. et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)-but not Th1-driven immunopathology. J. Exp. Med. 193, 785-792 (2001).
47. Prefontaine, D. et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J. Immunol. 183, 5094-5103 (2009).
48. Kearley, J., Buckland, K. F., Mathie, S. A. & Lloyd, C. M. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am. J. Respir. Crit. Care Med. 179, 772-781 (2009).
49. Kondo, Y. et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int. Immunol. 20, 791-800 (2008).
50. Liu, X. et al. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem. Biophys. Res. Commun. 386, 181-185 (2009).
51. Hoshino, K. et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J. Exp. Med. 190, 1541-1548 (1999).
52. Mangan, N. E., Dasvarma, A., McKenzie, A. N. & Fallon, P. G. T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation. Eur. J. Immunol. 37, 1302-1312 (2007).
53. Kung, T. T. et al. Mast cells modulate allergic pulmonary eosinophilia in mice. Am. J. Respir. Cell. Mol. Biol. 12, 404-409 (1995).
54. Weinberg, E. O. et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106, 2961-2966 (2002).
55. Shimpo, M. et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109, 2186-2190 (2004).
56. Weinberg, E. O. et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107, 721-726 (2003).
57. Haga, Y. et al. The effect of ST2 gene product on anchorage-independent growth of a glioblastoma cell line, T98G. Eur. J. Biochem. 270, 163-170 (2003).
58. Hudson, C. A. et al. Induction of IL-33 expression and activity in central nervous system glia. J. Leukoc. Biol. 84, 631-643 (2008).
59. Kanda, M. et al. Elevation of ST2 protein levels in cerebrospinal fluid following subarachnoid hemorrhage. Acta Neurol. Scand. 113, 327-333 (2006).
60. Onda, H. et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J. Cereb. Blood Flow Metab. 19, 1279-1288 (1999).
61. Chapuis, J. et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol. Psychiatry 14, 1004-1016 (2009).
62. Verri, W. A. Jr et al. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc. Natl Acad. Sci. USA 105, 2723-2728 (2008).
63. Xu, D. et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl Acad. Sci. USA 105, 10913-10918 (2008).
64. Palmer, G. et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 60, 738-749 (2009).
65. Werenskiold, A. K., Hoffmann, S. & Klemenz, R. Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Mol. Cell. Biol. 9, 5207-5214 (1989).
66. Tago, K. et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem. Biophys. Res. Commun. 285, 1377-1383 (2001).
67. Yanagisawa, K., Takagi, T., Tsukamoto, T., Tetsuka, T. & Tominaga, S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett. 318, 83-87 (1993).
68. Thomassen, E. et al. Role of cell type-specific promoters in the developmental regulation of T1, an interleukin 1 receptor homologue. Cell Growth Differ. 6, 179-184 (1995).
69. Leung, B. P., Xu, D., Culshaw, S., McInnes, I. B. & Liew, F. Y. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J. Immunol. 173, 145-150 (2004).